Photo Credit: 502499878
The following is a summary of “Daratumumab-based regimen for newly diagnosed multiple myeloma patients with paraskeletal plasmacytomas: a retrospective study in a single center” published in the November 2024 issue of Hematology by Xu et al.
Researchers conducted a retrospective study to analyze the efficacy of daratumumab-based regimens in patients suffering from newly diagnosed multiple myeloma (NDMM) with paraskeletal plasmacytomas (PPs).
They retrospectively analyzed the medical data of 28 patients suffering from NDMM with PPs. The patients were divided into 2 groups: group A, treated with a daratumumab-based regimen, and group B, treated with a daratumumab-free regimen. They compared risk factors, efficacy, and overall survival (OS) between the 2 groups.
The results showed that univariate COX regression analysis identified grouping and creatinine as significant factors. The HR for group A was 0.30 (0.10-0.88, P = 0.029), indicating a protective effect, while creatinine had an HR of 1.00 (1.00-1.01, P = 0.026), indicating a risk factor. Efficacy was significantly better in group A (P = 0.025), and OS differed significantly between the 2 groups (54:27, P = 0.002).
They concluded that daratumumab-based regimens improved OS in MM with extramedullary disease. The findings suggested that these regimens should be prioritized for such patients.
Source: tandfonline.com/doi/full/10.1080/16078454.2024.2431958
